Presenting the Future Home of Tevogen Bio
Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly global headquarters in New Jersey. This facility will serve as the company’s central hub for research and development, manufacturing, and distribution of its investigational T cell therapies for COVID-19, other viral infections and oncology. The 160-thousand square foot facility will bring nearly 1,800 life sciences jobs to New Jersey, leveraging the state’s rich history and support structure for medical innovation. The headquarters will be powered, in part, by renewable energy based on solar and other environmentally-friendly technologies. Congratulations to our team of visionary architects and lab engineers!
Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University
Businesswire – May 11th, 2021
Businesswire – April 12th, 2021
Cell & Gene – March 23rd, 2021
Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19
Businesswire – March 15th, 2021
Newswire – January 25th, 2021
Newswire – October 14th, 2020
6ABC – August 20th, 2020
Newswire – August 10th, 2020
Newswire – July 15th, 2020
© 2021 Tevogen Bio. All Rights Reserved.